Introduction
Basal cell carcinoma (BCC) is not only the most common skin tumor but also the most frequent malignancy in the Caucasian population (Diepgen and Mahler, 2002) . The cancer most likely originates from epidermal stem cells or from undifferentiated cells of the outer root sheath of hair follicles (Owens and Watt, 2003; Hutchin et al., 2005) and its formation at the molecular level is mostly associated with dysregulated Hedgehog (Shh) signaling in combination with or without mutations in the p53 suppressor gene (Ziegler et al., 1994; Dahmane et al., 1997; Xie et al., 1998; Hutchin et al., 2005) . The Shh signaling pathway regulates cell cycle, cell growth and tissue patterning during development and apoptosis (reviewed by Cohen, 2003) . In addition, it is also active in terminally differentiated but actively dividing cells such as hair follicle cells and cells located in the basal layer of the epidermis, where it regulates cell renewal (Callahan and Oro, 2001) . If Shh proteins bind to the membrane receptor patched, the activation of another cell membrane receptor, smoothened, is triggered allowing Glioma-associated (Gli) transcription factors to translocate to the nucleus where they bind to and induce transcription of the Shh target genes essential for cell cycle and cell growth. Therefore, it is obvious that uncontrolled Shh signaling, for example, due to mutations in the patched or smoothened gene may have an oncogenic potential. In fact, patched mutations are found in up to 38% of sporadic BCC and up to 88% of xeroderma pigmentosum (Daya-Grosjean and CouvePrivat, 2005) , a precancerous state of BCC (Miller et al., 2006) . Gli transcription factors seem to be important mediators of the oncogenic Hedgehog signaling (reviewed by Kasper et al., 2006) . Three Gli genes (Gli1, Gli2 and Gli3) have been identified in humans. They code for large (>1000 amino acids) five-finger zinc-finger transcription factors, which bind DNA target sequences with the last three zinc fingers (Pavletich and Pabo, 1993) . They have partially redundant and partially distinct functions, they activate different target genes and presumably act in a combinatorial manner (Nguyen et al., 2005; Eichberger et al., 2006) . While Gli1 possesses only an activation domain, Gli2 and Gli3 contain both activation and repression domains. Gli2 seems to be the primary positive transducer of Hedgehog signaling. This view is based on the findings that (a) Gli1 À/À mice are viable and have no obvious defects, whereas Gli2 À/À mice are lethally defective similar to Shh À/À mice (Park et al., 2000) ; (b) in case of experimental Shh peptide overexpression, removal of Gli2, but not of Gli1, rescues the normal phenotype (Bai et al., 2002) ; and (c) hair follicle development has clearly been shown to be dependent on Gli2, whereas Gli1 seems to play a subsidiary role (Mill et al., 2003) .
As with most tumors, an important feature of BCC is its resistance to apoptosis, although the detailed molecular mechanism is unclear. Recently, it was found that Gli1 or Gli2 overexpression upregulated Bcl-2, a key molecule involved in the prevention of the intrinsic apoptotic pathway (Bigelow et al., 2004; Regl et al., 2004b) . However, whether the dysregulated Shh signaling pathway also influences resistance of BCC to the extrinsic, for example, death ligand/receptor-mediated apoptotic pathway has not been described so far. Here, we report that Gli2 overexpression upregulates cFlip, which antagonizes death ligand/receptor-mediated apoptosis at the caspase 8 level. Moreover, cFlip was identified as direct transcriptional target of Gli2, as Gli2 binding sites have been characterized in the cFlip promoter. Gli2 gene silencing by RNA interference downregulated cFlip expression and reversed apoptosis resistance.
Results

cFlip expression is upregulated by Gli2
The role of Gli2 in the apoptosis resistance was studied using a keratinocytic cell line, HaCaT NHis-Gli2 (NHis-Gli2) (Regl et al., 2004a) , in which Gli2 expression is under the control of tetracycline (tet). By assessing Gli2 expression in tet-induced or untreated NHis-Gli2 cells and mock-transfected HaCaT control cells, Gli2 mRNA was found to be at least 12 times upregulated in tet-induced NHis-Gli2 but not in the control cells as detected by real-time reverse transcriptase-PCR (Figure 1a) . Correspondingly, Gli2 protein expression as detected by western blots was only induced in tet-treated NHis-Gli2 but not in control cells (Figure 1b) . In time-course experiments, Gli2 protein was detected 6 h after tet induction and increased over the next 48 h as identified by bands at 130 and 260 kDa, which correspond to Gli2 monomer and dimer, respectively (Figure 1b ). In accordance with Regl et al. (2004b) , Bcl-2 expression was upregulated both at mRNA and protein levels by Gli2 tet induction (Figures 1c and d) . Time-course experiments for Gli2 and cFlip mRNA (Supplementary Figure 1) paralleled the protein expression.
In Affymetrix gene chip analysis using the human U133A_2 gene chip, an upregulation of cFlip, which inhibits apoptosis at the level of caspase 8 (Irmler et al., 1997) , was detected in tet-induced NHis-Gli2 cells (data not shown). Therefore, cFlip mRNA and protein expression in dependence of Gli2 levels was assessed. Parallel to the Gli2 increase, cFlip mRNA levels were Apoptosis regulation by Gli2 in BCC E Kump et al increased in NHis-Gli2 but not in the control cells 72 h after tet induction (Figure 1e ). Upregulation of cFlip protein was manifested after 12 h and levels increased within 48 h (Figure 1f ). In addition to Bcl-2 used as a control, another known Gli2-regulated target, Gli1, was also studied. As expected, in time kinetic studies, Gli1 mRNA levels closely paralleled Gli2, cFlip and Bcl-2 mRNA levels (Supplementary Figure 1) . The rapid response of cFlip to Gli2 expression suggested a direct regulation of the cFlip gene by Gli2. Therefore, Gli2 binding sites were searched in the cFlip promoter.
Characterization of Gli2 binding sites in the cFlip promoter So far, the promoter of the human cFlip gene has not been revealed. Studies of Gli2 binding sites in three other known direct Gli2 target genes, Gli1, Bcl-2 and FoxE1, showed that these promoters have the consensus Gli binding sequence 5 0 -GACCACCCA-3 0 (Kinzler and Vogelstein, 1990; Eichberger et al., 2004; Ikram et al., 2004; Regl et al., 2004b) . Thus, published sequences upstream of the cFlip coding region (NCBI accession no. AB038972) were studied in detail by the Nucleic acid pattern search at EMBOSS, Pasteur (http://bioweb.pasteur. fr/seqanal/interfaces/fuzznuc.html) for the identification of potential Gli2 binding motives. Four clusters of candidate binding sites (Table 1 and Figure 2a) were predicted, each candidate differing with no more than two mismatches from the known consensus sequence. As control, the Gli2 binding sites on the Bcl-2 promoter are listed too (Table 1) . To address which of these candidate clusters contain a potential Gli2 binding site, the corresponding DNA fragments, including Bcl-2's Gli2 binding site, were PCR amplified and orientationally cloned into a promoter reporter vector. After confirmation by sequencing, promoter activities were evaluated for all candidate clusters. As shown in Figure 2b , upon tet treatment, the cells showed a significant increase in luciferase activity for cluster II as well as with the positive control Bcl-2 promoter. The data obtained are consistent with the above sequence prediction (Table 1) , with cluster II comprising two candidate Gli2 binding sites, one having one mismatch and the other having two mismatches. Thus, cluster II was further investigated.
To confirm the binding of Gli2 to the putative Gli2 binding sites (bs 2 and bs 3 ; Table 1) in the cFlip promoter, we performed electrophoretic mobility shift assays. Double-stranded oligos (44 bp) were designed and chemically synthesized with the central 9 bp sequence flanked by 17 or 18 bp, which are the same sequences as those in the original genomic DNA. The known Gli2 binding consensus sequence of the Bcl-2 promoter (bs con ) served as a positive control and a mutated sequence 5 0 -GACCAGGCG-3 0 as negative control . Among these oligos, all sense strands were radiolabeled. After incubation of the oligos with nuclear protein extracts from NHis-Gli2 cells, a shifted band was observed with oligos for bs 2 , bs 3 and positive control bs con (Figure 2c ), whereas no bandshifts occurred with the negative control (Supplementary Figure 2 ). When the nuclear protein extracts were preincubated with a Gli2 antibody, a supershifted band appeared confirming Gli2 to be involved in the bandshift. As expected, the shifted bands for bs 2 and bs 3 , as well as the control bs con , were stronger with the nuclear protein extracts from tet-induced cells than from uninduced cells (Figure 2c ). Furthermore, the shifted signals were fading in a dose-dependent manner when an excess of unlabeled oligo for bs con was added as a competitor, confirming that Gli2 specifically binds to bs 2 and bs 3 (Figure 2d ).
To confirm the above observation, site-directed mutation was introduced into bs 2 or/and bs 3 , the active promoter reporter construct (containing cluster II), by PCR (Materials and methods in Supplementary Information). Promoter activity evaluation assays showed that site-directed mutation within either bs 2 or bs 3 markedly reduced luciferase activity. Moreover, no activity was left with the double-mutation construct (Figure 2e ). Taken together, these data demonstrate that Gli2 directly induces cFlip gene expression by specifically binding to the cFlip promoter. Apoptosis regulation by Gli2 in BCC E Kump et al High Gli2 expression protects cells from apoptosis NHis-Gli2 and the mock-transfected control HaCaT cells express TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) receptor 1 (data not shown) and undergo apoptosis when incubated with TRAIL, allowing us to study cFlip function. Figure 3a shows that about 30% of NHis-Gli2 cells became apoptotic upon incubation with TRAIL for 36 h as measured by DNA fragmentation (propidium iodide staining in fluorescence-activated cell sorting). However, the percentage of apoptotic cells was strongly reduced when Gli2 was upregulated with tet. This reduction was not found in HaCaT control cells where tet treatment did not upregulate Gli2 (Figure 3a) . Thus, high expression of Gli2 provides a protective effect for NHis-Gli2 cells, preventing TRAIL-mediated apoptosis. These results were confirmed using the Apopercentage assay kit. A red dye specifically binds to apoptotic cells, as they flip membrane components inside out. The dye is only taken up by apoptotic cells (black dots in Figure 3b ). Figure 3b shows that Gli2 or cFlip gene silencing with the corresponding specific small interfering RNA (siRNA) broke the apoptotic resistance of NHis-Gli2 cells. Thus, not only in uninduced cells (Gli2 low) but also in tet-induced cells (Gli2 high) TRAIL-mediated apoptosis could be markedly increased if the cells were transfected with siRNA against cFlip compared to control green fluorescent protein (GFP)-specific siRNAs, whereas no significant changes were detected without TRAIL treatment. Gli2 gene silencing with Gli2-specific siRNA showed a similar, albeit somewhat lower, result as with cFlip-specific siRNA (Figure 3b ), because in uninduced cells endogenous Gli2 expression is low and in induced cells the overexpressed Gli2 cannot become completely silenced. These results strongly support our hypothesis that Gli2 overexpression protects NHis-Gli2 cells from TRAIL-induced apoptosis through upregulation of cFlip expression. Interaction of TRAIL with its receptors induces caspase 8 activation. Indeed, tet-induced high expression of Gli2, which upregulates cFlip (Figure 1 ), resulted in a markedly reduced caspase 8 activation (Figure 4a ). In Table 1 ) are indicated. (b) A luciferase reporter assay was used to evaluate the promoter activity upon tet induction (Gli2 high). The known region from Bcl-2 served as positive control and mock plasmid as negative control. The relative luminescence levels were normalized to that in mock-transfected untreated cells (Gli2 low), which was set to 1. (c) A shifted band was detected when 32 P-radiolabeled double-stranded oligos for bs con , bs 2 or bs 3 were preincubated with nuclear extracts from tetinduced or uninduced NHis-Gli2 cells. A supershifted band appeared when specific anti-Gli2 antibody was added to the nuclear extracts. (d) The shifted bands were fading in a dose-dependent manner in competition assays with an excess of unlabeled oligo for bs con as a competitor. Numbers (1, 10, 100, 400) indicate the multitude of excess competitor used. Data for the mutated negative control oligo are not shown. (e) The same luciferase reporter assay was performed as described in panel b. BM2, mutated bs 2 construct; BM3, mutated bs 3 construct; double mutant, both bs 2 and bs 3 mutated construct. Data represent the mean±s.d. of more than three experiments (b, e), or of three different experiments (c, d). Statistical significance (b, e): *Po0.01.
Apoptosis regulation by Gli2 in BCC E Kump et al addition, cFlip gene silencing induced by specific siRNA clearly increased caspase 8 activity (Figure 4a , right bars) and rendered cells susceptible to apoptosis even when Gli2 was highly expressed (Figure 4b , right bars), whereas control GFP-siRNA had no effect (Figure 4b , middle bars). In support of this, western blot analysis of NHis-Gli2 cells treated with soluble recombinant TRAIL showed that procaspase 8 decreased, whereas the p20 cleavage fragment of caspase 8 increased (Figure 4c ). However, this change was not seen in the tet-on condition because high cFlip expression inhibited the cleavage of procaspase 8. These data indicate that caspase 8 activity inversely correlated to cFlip expression, supporting the hypothesis that high Gli2 expression protects NHis-Gli2 cells from TRAIL-mediated apoptosis at the level of caspase 8 activation via the upregulation of cFlip.
Gli2 regulates cFlip expression in BCC tissue
To address whether Gli2 regulates cFlip expression in vivo, human BCC biopsies or excisions obtained from different patients were investigated for the expression of Gli2, cFlip or control Bcl-2 ( Figure 5 ). BCC cryosections stained with Gli2, cFlip or Bcl-2 antibodies showed that high Gli2 expression correlated with high expression of cFlip or Bcl-2 (Figure 5a ). In addition, gene silencing of Gli2 in cultured BCC with the specific (siGli2) but not with a nonspecific control siRNA (siGFP) showed a significant lower Gli2 expression (27% residual Gli2 expression) in tumor tissue Figure 3) . Moreover, when the Gli2 gene was silenced, both cFlip and Bcl-2 expression (each 40% residual) was also significantly lowered ( Figure 5b and Supplementary Figure 3) .
Gli2 gene silencing in BCC tissue ex vivo renders BCC cells sensitive to TRAIL-mediated cell death
As TRAIL receptor 2 is expressed on BCC cells (data not shown), we induced apoptosis with soluble human TRAIL (200 ng ml À1 for 30 h or 25 ng ml À1 for 14 h) in Figure 5 Gli2 regulates cFlip in human BCC tissues and renders BCC cells sensitive to cell death. (a) Consecutive cryosections from the same patient were stained with Gli2-, Bcl-2-or cFlip-specific antibodies. Tumor areas with an overlapping expression pattern for the three molecules are shown (arrows). (b) BCC tissues were cut into small pieces. Each of them was transfected with Gli2-siRNA (siGli2) or control GFP-siRNA (siGFP) or without any siRNA (nil), and cultured for 3 days. Cryosections were made and stained to detect Gli2, Bcl-2 or cFlip. To quantitate their expression, computer-assisted image analysis was performed (Bachmann et al., 2001) . The values obtained from the transfected sections were compared with the untransfected (nil) sections, which were set to 100%. (c) Tissue sections from the same BCC were first transfected with or without Gli2-siRNA, Flip-siRNA or control GFP-siRNA and then treated with soluble TRAIL to induce apoptosis. The cryosections (8 mm) were TUNEL-stained combined with DAPI staining. Red staining shows rhodamine-labeled apoptotic cells and blue staining shows DAPI-labeled nuclei. The results shown represent the mean ± s.d. of four experiments (b), or are representative of three different experiments (a, c). Scale bars: 50 mm. BCC, basal cell carcinoma; siRNA, small interfering RNA; GFP, green fluorescent protein; TRAIL, tumor necrosis factor-related apoptosis-inducing ligand; TUNEL, TdT-mediated dNTP nick end labeling; DAPI, 4 0 ,6-diamidino-2-phenylindole.
Apoptosis regulation by Gli2 in BCC E Kump et al BCC tissue sections that had been either pretreated with/without Gli2-siRNA, Flip-siRNA or control GFPsiRNA. Cell morphology in cryosections from tissues (200 ng ml À1 TRAIL induction for 30 h) showed that more dead cells appeared after Gli2 gene silencing in the areas where BCC nodules were stained with the BCC marker BerEP4 antibody, while less such cells were found in untreated or control GFP-siRNA-treated tissue (data not shown). The TUNEL (TdT-mediated dNTP nick end labeling) assay was performed with weaker TRAIL-induced tissues (25 ng ml À1 for 14 h), confirming the morphological observation. Significantly more TUNEL-positive cells (rhodamine-labeled red staining) were found in the cryosections from tissues treated by Gli2-siRNA or cFlip-siRNA compared to those from untreated or control GFP-siRNA tissues, clearly indicating that Gli2 gene silencing or cFlip gene silencing is responsible for the increased apoptosis ( Figure 5c ). Thus, the observations made both with BCC tissues ex vivo (Figure 5c ) or HaCaT cells in vitro (Figure 3b ) strongly demonstrate that Gli2 renders cells resistant to TRAIL-mediated apoptosis via cFlip upregulation.
Discussion
To circumvent the attack of the immune system, tumors including skin tumors develop various evasion mechanisms. They expose death ligands, which may kill attacking immune effector cells (reviewed by Igney and Krammer, 2005) , they downregulate the expression of death receptors (Bachmann et al., 2001 ) and/or upregulate molecules that interfere with apoptotic pathways (Trisciuoglio et al., 2005) . BCCs highly express Fas ligand, but not the corresponding receptor Fas (Buechner et al., 1997) . This may make the tumor resistant to the attack of Fas-positive immune effector cells . In addition, although BCC cells express TRAIL and TRAIL receptor 2, the tumor cells do not kill themselves. One important reason is the high expression of the antiapoptotic cFlip in this tumor .
As in many BCCs the Gli transcription factors are overexpressed, we investigated whether Gli2 contributes to the immune evasion of BCC by increasing its apoptosis resistance via regulating apoptosis-related molecules. Indeed, we found that Gli2 directly upregulates the expression of cFlip, which is an inhibitor of the extrinsic apoptotic pathway at the level of caspase 8 (Irmler et al., 1997) . Performing electrophoretic mobility shift analysis, it was clearly established that Gli2 binds to the cFlip promoter and two Gli2 binding sites (bs 2 and bs 3 ; Table 1 and Figure 2 ) were identified. Both bs 2 and bs 3 had one or two mismatches to the Gli consensus sequence 5 0 -GACCACCCA-3 0 , which had been earlier shown to be bound by Gli1 and Gli2 (Kinzler and Vogelstein, 1990; Ruiz i Altaba, 1999) . Of interest, none of the binding sequences showed interaction with Gli1, as there was no supershift with anti-Gli1 antibody (data not shown). However, this might have been a sensitivity problem, as Gli2 protein was overexpressed relative to Gli1; thus, the Gli1 supershift may just not have been visible.
The observation that Gli2-regulated expression of cFlip and Bcl-2 established in the keratinocytic cell line is consistent with the high expression of cFlip (Figure 5a ) and Bcl-2 (Delehedde et al., 1999) detected in BCC. It is therefore predictable that a similar Gli2-mediated cFlip/Bcl-2 regulation may be operative in BCC. Our results suggest that this is indeed the case in BCC tissues. Using Gli2-specific siRNAs, which have been successfully transfected into BCC tissues , it was possible to determine the expression of the Gli2 target genes, cFlip and Bcl-2, in dependence from Gli2 levels. As predicted, the expression of cFlip and Bcl-2 was significantly lowered in BCC tissues upon Gli2 gene silencing, clearly establishing the direct link between Gli2 and the two antiapoptotic genes (Figure 5b) .
The direct binding of Gli2 to the cFlip promoter has consequences for apoptosis. Uninduced NHis-Gli2 cells, which express basal levels of Gli2 and cFlip, became apoptotic upon incubation with soluble TRAIL. Upregulation of Gli2 by tet markedly suppressed TRAILinduced apoptosis due to the Gli2-mediated cFlip upregulation (Figures 3 and 4) . Indeed, lowering cFlip expression with cFlip-specific siRNA restored the sensitivity of these cells to apoptosis. Similarly, downregulating Gli2 expression with specific siRNA-Gli2 also increased apoptosis by lowering cFlip expression (Figures 5b and c) as did the direct Flip gene silencing with siRNA-Flip, confirming that cFlip is a downstream target of Gli2. Of importance, we have been able to show this Gli2-cFlip interaction also in BCC tissues.
Our study provides clear evidence that the resistance of BCC to apoptosis is due to high cFlip and Bcl-2 expression, which is the direct consequence of high Gli2 expression. Thus, Gli2 could serve as a prime target for a novel therapeutic approach in tumors with dysregulated Hedgehog signaling. Indeed, downregulating Gli2 by specific siRNA made the BCC sensitive to the extrinsic apoptotic pathway. Our data are strongly supported by animal experiments. Using genetically engineered mice in which the expression of Gli2 could be turned on or off, Hutchin et al. (2005) showed that high Gli2 expression resulted in BCC-like tumor formation, while low Gli2 brought the tumors into regression. We used a high Gli2-expressing tumor cell line to form tumors in nude mice. Silencing Gli2 in the tumor cells by specific short hairpin RNAs significantly inhibited the BCC-like growth in vivo (Ji et al., 2008) .
Materials and methods
Cell lines and BCC specimens
HaCaT NHis-Gli2 and HaCaT control cells were kindly obtained from Dr F Aberger and Dr G Regl (University of Salzburg, Salzburg, Austria). NHis-Gli2 expression was induced by the addition of 2.5 mg l À1 tet to the medium for 72 h. BCC specimens from biopsies or surgical excision were obtained from 17 patients. Upon staining for high Gli2 expression, BCC specimens obtained from 13 patients were further used. The short-term culturing of BCC tissue has been described elsewhere . The work with BCC has been approved by the ethical committee of the University Hospital Basel. Written consent was obtained from the patients.
RNA interference RNA interference in cells or BCC was performed as described previously . The selection of the optimal siRNAs and their efficacy in gene silencing at protein and mRNA level are shown in Supplementary Figure 4 .
RNA isolation and TaqMan reverse transcriptase-PCR RNA was isolated using the RNeasy mini kit (Qiagen, Hombrechtikon, Switzerland), and cDNA was synthesized with Moloney Murine Leukemia Virus reverse transcriptase (Invitrogen, Paisley, UK), according to the manufacturer's instructions. Quantitative mRNA measurements were carried out by reverse transcriptase-PCR on an Mx4000 cycler (Stratagene, La Jolla, CA, USA) using qPCR Rox&Go mastermix (Q-Bio gene, Morgan Irvine, CA, USA), with glyceraldehyde 3-phosphate dehydrogenase as a normalizer, according to the manufacturer's instructions.
Protein analysis
Protein analysis (fluorescence-activated cell sorting, western blots, immunohistochemistry) was performed by standard procedures. Nuclear and cytoplasmatic protein lysates were prepared as described in Material and methods in Supplementary Information. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis gels (7.5 or 10%) were used depending on the protein of interest. Anti-caspase 8 p20 (H-134) (1 mg ml
À1
) and anti-human Gli2 (H-300) (1 mg ml À1 ) for western blots or electrophoretic mobility shift assay and anti-human Gli2 (N-20) (0.5 mg ml
) for immunohistochemistry were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Antihuman Bcl-2 (ready-to-use), anti-human epithelial antigen (Ber-EP4) (ready-to-use), horseradish peroxidase-conjugated antibodies (goat anti-rabbit, goat anti-mouse), biotinylated antibodies (rabbit anti-goat, goat anti-rabbit, goat anti-mouse) and isotype controls were obtained from Dako (Glostrup, Denmark). Anti-human b-actin (0.3 mg ml
) was obtained from Abcam (Cambridge, UK). Anti-human cFlip rabbit antibody was prepared in our lab (Bachmann et al., 2001) .
Characterization and confirmation of Gli2 binding sites Detailed procedures are described in Materials and methods in Supplementary Information.
Apoptosis induction and assays
Cultured cells were induced to apoptosis using soluble recombinant TRAIL (100 ng ml À1 ) (Alexis, Lausen, Switzerland) that had been preincubated for 10 min on ice with a cross-linking enhancer for ligands (2 mg ml À1 ) (Alexis). Apoptosis was evaluated using standard procedures at 16 h post-induction for caspase 8 activity, 24 h post-induction using the Apopercentage assay (Biocolor Ltd, Newtownabbey, Northern Ireland, UK) or 36 h post-induction for detection of DNA fragmentation. BCC tissue sections were induced to apoptosis for 14 or 30 h using the preincubated soluble recombinant TRAIL (25-200 ng ml À1 ) after they had been treated by different siRNAs for 36 h. Cell death of BCC was determined by TUNEL assay using the ApopTag Red in situ apoptosis detection kit (Chemicon International, Temecula, CA, USA), according to the manufacturer's protocol (Ji et al., 2008) , or morphologically by microscopy.
Statistical analysis
Results are shown as mean ± s.d. Unpaired Student's t-test was used for statistical analysis.
